Table 2.

Results of conditional logistic regression for the selected biomarkers

VariableRisk ratioP95% Confidence limits
LowerUpper
PAH-albumin (Ln)*0.920.710.611.41
ras p21 (Ln)0.960.520.851.09
CYP1A1 MspI0.630.200.321.26
CYP1A1 Ile462Val§0.270.090.061.24
CYP2D6A0.500.400.102.48
CYP2D6B0.940.820.561.59
NAT1*100.870.610.501.50
NAT2 slow**0.760.320.451.30
CYP2D6A, CYP2D6B††1.070.920.303.76
  • NOTE: This model did not include β-carotene assignment. Results are not materially altered by inclusion of treatment.

  • * The risk ratio comparison for PAH-albumin (Ln) is based on one log unit of PAH-albumin.

  • The risk ratio comparison for ras p21 (Ln) is based on one log unit of ras p21.

  • The risk ratio comparison for any CYP1A1 MspI allele (heterozygous or homozygous MspI genotypes) versus non-MspI homozygous genotype.

  • § The risk ratio comparison for any CYP1A1 462 Val allele (heterozygous or homozygous) versus 462 Ile/Ile genotype.

  • The risk ratio comparison for CYP2D6A is based on any A allele versus wild type.

  • The risk ratio comparison for CYP2D6B is based on any B allele versus wild type.

  • ** Risk ratio comparison for NAT2 is based on slow acetylator genotypes versus rapid genotypes (21).

  • †† The risk ratio comparison for CYP2D6 is based on slow metabolism genotypes versus rapid genotypes (19).